05. Blinova YeV, Meleshkin AI, Yakhya MKhS, Vasilkina OV, Kovyshkin AG, Abrosimov AV, Kurganov NA, Yelizarova YuN, Blinov DS. On anti-ischemic and anti-hypoxic activity of the novel compound of (RS) 4-Nytro-N-Benzamid.

LATEST ISSUE

For readers

For authors

FOR REVIEWERS

SOCIAL NETWORKS

Engineering Technologies and Systems is an open access journal, which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author in accordance with the BOAI definition of open access.

All the materials of the “Engineering Technologies and Systems” journal are made available under a Creative Commons «Attribution» 4.0 license.

Useful Materials

To download article.

UDC 615.21

DOI: 10.15507/0236-2910.026.201603.349-358

ON ANTI-ISCHEMIC AND ANTI-HYPOXIC ACTIVITY OF THE NOVEL COMPOUND OF (RS) 4-NYTRO-N- [1-PHENYL-5-(DIETHYLAMINO)PENTHYL]BENZAMID

Yekaterina V. Blinova
professor of Faculty Surgery chair, Medical Institute, National Research Mordovia State University (68, Bolshevistskaya St, Saransk, Russia), Dr.Sci. (Medicine), ORCID: http://orcid.org/0000-0003-0050-0251, This email address is being protected from spambots. You need JavaScript enabled to view it.

Aleksandr A. Meleshkin
Ph.D. candidate of Faculty Surgery chair, Medical Institute, National Research Mordovia State University (68, Bolshevistskaya St, Saransk, Russia), ORCID: http://orcid.org/0000-0002-3538-2091, This email address is being protected from spambots. You need JavaScript enabled to view it.

Olga V. Vasilkina
post-graduate student of Faculty Surgery chair, Medical Institute, National Research Mordovia State University (68, Bolshevistskaya St, Saransk, Russia), ORCID: http://orcid.org/0000-0003-0881-8002, This email address is being protected from spambots. You need JavaScript enabled to view it.

Aleksey V. Abrosimov
student of Medical Institute, National Research Mordovia State University (68, Bolshevistskaya St, Saransk, Russia), ORCID: http://orcid.org/0000-0001-6539-5363, This email address is being protected from spambots. You need JavaScript enabled to view it.

Mukhammed Khasan Salam Yakhya
post-graduate student of Faculty Surgery chair Medical Institute, National Research Mordovia State University (68, Bolshevistskaya St, Saransk, Russia), ORCID: http://orcid.org/0000-0003-3880-0276, This email address is being protected from spambots. You need JavaScript enabled to view it.

Andrey G. Kovyshkin
Ph.D. candidate of Faculty Surgery chair, Medical Institute, National Research Mordovia State University (68, Bolshevistskaya St, Saransk, Russia), ORCID: http://orcid.org/0000-0002-6247-2252, This email address is being protected from spambots. You need JavaScript enabled to view it.

Nikolay A. Kurganov
post-graduate student of Faculty Surgery chair, Medical Institute, National Research Mordovia State University (68, Bolshevistskaya St, Saransk, Russia), ORCID: http://orcid.org/0000-0002-1590-4438, This email address is being protected from spambots. You need JavaScript enabled to view it.

Yuliya N. Yelizarova
post-graduate student of the Out-Patient Therapy chair, Medical Institute, National Research Mordovia State University (68, Bolshevistskaya St, Saransk, Russia), ORCID: http://orcid.org/0000-0003-4764-2177, This email address is being protected from spambots. You need JavaScript enabled to view it.

Dmitriy S. Blinov
director of the Center for Advanced Study of innovative medicines, National Research Mordovia State University (68, Bolshevistskaya St, Saransk, Russia), Dr.Sci. (Medicine), professor, ORCID: http://orcid.org/0000-0002-8385-4356, This email address is being protected from spambots. You need JavaScript enabled to view it.

Introduction: The recent studies demonstrated acute toxicity data and antiarrhythmic activity of a novel compound 4-Nytro-N-[1-Phenyl-5-(Diethylamino) Penthyl]Benzamid. These results allow us to suggest the presence of anti-ischemic and anti-hypoxic activities in the compound.
Materials and Methods: The experiments have been carried out in male rats by differential staining method of heart’s necrotic and ischemic zones size dimension; asphyxiation and hyper carbonic hypoxia were set in mice. The inotropic activity of the compound was studied in rat’s isolated hypoxic heart by Langendorf method.
Results: The experiment in rats with acute myocardial infarction shows that preventive intravenous administration of 1,7 mg/kg (it corresponds with 5 % DL50 index for mice) L-glutamic compound of 4-Nytro-N-[1-Phenyl-5(Diethylamino) Penthyl] Benzamid (laboratory name LCT-H102) solution leads to heart’s necrotic zone restriction. Isolated rat’s heart perfusion by 10-5 M LCT-N102 solution demonstrates positive inotropic activity. The compound administered by the mentioned way, prolongs both bioelectric cardiac activity and life expectancy of mice with experimental acute asphyxiation and hyper carbonic hypoxia. Considering these results we can constitute with high probability that LCT-N102 anti-ischemic effect is a consequence of its anti-hypoxic activity as well as myocardial bioelectric process optimization.

Keywords: ischemia, hypoxia, LCT-N102, L-glutamic compound of 4-Nytro-N-[1-Phenyl-5(Diethylamino)Penthyl]Benzamid, antiischemic activity, bioelectric activity, inotropic effect, ischemic and necrotic zones

For citation: Blinova YeV, Meleshkin AI, Yakhya MKhS, Vasilkina OV, Kovyshkin AG, Abrosimov AV, Kurganov NA, Yelizarova YuN, Blinov DS. On anti-ischemic and anti-hypoxic activity of the novel compound of (RS) 4-Nytro-N-[1-Phenyl-5-(Diethylamino) Penthyl]Benzamid. Vestnik Mordovskogo universiteta = Mordovia University Bulletin. 2016; 3(26):349-358. DOI: 10.15507/0236-2910.026.201603.349-358

Acknowledgements: The authors are extremely grateful to State Prize Laureate Prof. S. Ya. Skachilova for the investigated compound, which has been synthesized under her authority.

This work is licensed under a Creative Commons Attribution 4.0 License.